Department of Endocrinology, University Hospital of Pisa, Via Cisanello 2, 56124 Pisa, Italy.
J Clin Endocrinol Metab. 2012 Nov;97(11):3974-82. doi: 10.1210/jc.2012-2406. Epub 2012 Sep 4.
Thyroglobulin autoantibodies (TgAb) have been proposed as a surrogate marker of thyroglobulin in the follow-up of differentiated thyroid carcinoma. Commercially available TgAb assays are often discordant. We investigated the causes of discrepancy.
TgAb were measured by three noncompetitive immunometric assays and three competitive RIA in 72 patients with papillary thyroid carcinoma and associated lymphocytic thyroiditis (PTC-T), 105 with papillary thyroid carcinoma and no lymphocytic thyroiditis (PTC), 160 with Hashimoto's thyroiditis, and in 150 normal subjects. The results of the six assays were correlated. TgAb epitope pattern, evaluated by inhibition of serum TgAb binding to thyroglobulin by TgAb-Fab regions A, B, C, and D, were compared in sera which were positive in all six assays (concordant sera) and positive in only one to five assays (discordant sera) were compared. TgAb International Reference Preparation (IRP) was measured in 2007 and 2009.
The correlations of the six assays ranged from -0.01 to 0.93 and were higher in PTC-T and Hashimoto's thyroiditis than in PTC and normal subjects. Two uncorrelated components, one including the three immunometric assays, the other the three RIA, explained 40 and 37% of the total variance of the results of the six assays. The levels of inhibition were higher in concordant sera than in discordant sera by TgAb-Fab region B (27.0%, 21.2-34.0 vs. 6.0%, and 2.7-12.7%) and region C (30.5%, 21.3-37.7 vs. 4.0%, and 1.0-6.5%); thus, the epitope pattern was more homogeneous in concordant sera than in discordant sera. TgAb IRP ranged from 157 to 1088 (expected 1000) IU/ml in 2009; results in 2007 were similar in all but two assays.
TgAb assays are highly discordant. Discrepancy is lower when comparing assays with similar methodology. Results of TgAb from PTC-T are more concordant than those from PTC because their epitope pattern is more restricted. The internal standardization of TgAb is generally, but not completely, satisfactory.
甲状腺球蛋白自身抗体(TgAb)已被提议作为分化型甲状腺癌随访中的甲状腺球蛋白的替代标志物。市售的 TgAb 检测方法往往存在不一致性。我们研究了这种差异的原因。
在 72 例伴有淋巴细胞性甲状腺炎的甲状腺乳头状癌患者(PTC-T)、105 例无淋巴细胞性甲状腺炎的甲状腺乳头状癌患者(PTC)、160 例桥本甲状腺炎患者和 150 例正常对照中,分别用三种非竞争免疫测定法和三种竞争放射免疫分析法测定 TgAb。比较了六种检测方法的相关性。用 TgAb-Fab 区域 A、B、C 和 D 抑制血清 TgAb 与甲状腺球蛋白的结合,评估 TgAb 表位模式,对在所有六种检测方法中均为阳性(一致性血清)和仅在一种至五种检测方法中为阳性(不一致性血清)的血清进行比较。在 2007 年和 2009 年测量了甲状腺球蛋白国际参考制剂(IRP)。
六种检测方法的相关性范围为-0.01 至 0.93,在 PTC-T 和桥本甲状腺炎中高于 PTC 和正常对照。两个不相关的成分,一个包括三种免疫测定法,另一个包括三种放射免疫分析法,解释了六种检测方法结果总方差的 40%和 37%。用 TgAb-Fab 区域 B(27.0%,21.2-34.0 对 6.0%,2.7-12.7%)和区域 C(30.5%,21.3-37.7 对 4.0%,1.0-6.5%),一致性血清的抑制水平高于不一致性血清;因此,一致性血清的表位模式比不一致性血清更单一。2009 年甲状腺球蛋白国际参考制剂(IRP)范围为 157 至 1088(预期为 1000)IU/ml;除两种检测方法外,2007 年的结果相似。
TgAb 检测方法高度不一致。当比较具有相似方法学的检测方法时,差异较小。PTC-T 的 TgAb 结果比 PTC 的结果更一致,因为它们的表位模式更受限制。TgAb 的内部标准化通常,但并非完全令人满意。